Oxygen supply to encapsulated therapeutic cells

Advanced Drug Delivery Reviews

Volumn 67-68, Issue , 2014, Pages 93-110

  Colton, Clark K ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Cell transplantation; Encapsulation; Hypoxia; Immunobarrier; Immunoisolation; Implanted devices; Oxygen supply

Indexed keywords

CELLS; CYTOLOGY; ENCAPSULATION; OXYGEN SUPPLY;

CELL TRANSPLANTATION; HYPOXIA; IMMUNO-ISOLATION; IMMUNOBARRIER; IMPLANTED DEVICE;

TISSUE;

OXYGEN;

ANIMAL; CELL SURVIVAL; CELL TRANSPLANTATION; DEVICES; DIFFUSION; GRAFT REJECTION; HUMAN; METABOLISM; PANCREAS ISLET TRANSPLANTATION; PROCEDURES;

ANIMALS; CELL SURVIVAL; CELL TRANSPLANTATION; DIFFUSION; GRAFT REJECTION; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; OXYGEN;

EID: 84898539493     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.02.007     Document Type: Review

References (239)

1. Omer A., Duvivier-Kali V., Fernandes J., Tchipashvili V., Colton C.K., Weir G.C. Long-term normoglycemia in rats receiving transplants with encapsulated islets. Transplantation 2005, 79(1):52-58.
2. Brauker J., Frost G.H., Dwarki V., Nijjar T., Chin R., Carr-Brendel V., Jasunas C., Hodgett D., Stone W., Cohen L.K., et al. Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents. Hum. Gene Ther. 1998, 9:879-888.
3. Schwenter F., Schneider B.L., Pralong W.F., Deglon N., Aebischer P. Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum. Gene Ther. 2004, 15:669-689.
4. Hasse C., Klock G., Schlosser A., Zimmermann U., Rothmund M. Parathyroid allotransplantation without immunosuppression. Lancet North Am. Ed. 1997, 350:1296-1297.
5. Buchser E., Goddard M., Heyd B., Joseph J.M., Favre J., de Tribolet N., Lysaght M., Aebischer P. Immunoisolated xenogeneic chromaffin cell therapy for chronic pain: initial clinical experience. Anesthesiology 1996, 85(5):1005-1012.
6. Kishima H., Poyot T., Bloch J., Dauguet J., Conde F., Dolle F., Hinnen F., Pralong W., Palfi S., Deglon N., et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a preclinical study in chronic MPTP-treated baboons. Neurobiol. Dis. 2004, 16:428-439.
7. Bloch J., Bachoud-Levi A.C., Deglon N., Lefaucheur J.P., Winkel L., Palfi S., Nguyen J.P., Bourdet C., Gaura V., Remy P., Brugieres P., Boisse M.-F., Baudic S., Cesaro P., Hantraye P., Aebischer P., Peschanski M. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete ciliary neurotrophic factor: results of a phase I study. Hum. Gene Ther. 2004, 15:968-975.
8. Aebischer P., Schluep M., Deglon N., Joseph J.-M., Hirt L., Heyd B., Goddard M., Hammang J.P., Zurn A.D., Kato A.C., et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 1996, 2(6):696-699.
9. Colton C.K., Avgoustiniatos E.S. Bioengineering in development of the hybrid artificial pancreas. J. Biomech. Eng. 1991, 113:152-170.
10. Colton C.K. Implantable biohybrid artificial organs. Cell Transplant. 1995, 4(4):415-436.
11. Avgoustiniatos E.S., Colton C.K. Effect of external oxygen mass transfer resistance on viability of immunoisolated tissue. Ann. N.Y. Acad. Sci. 1997, 831:145-167.
12. Avgoustiniatos E.S., Colton C.K. Design considerations in immunoisolation. Principles of Tissue Engineering 1997, 333-346. R.G. Landes, Austin, TX. R. Lanza, R. Langer, W. Chick (Eds.).
13. Avgoustiniatos E.S., Wu H., Colton C.K. Engineering challenges in immunoisolation device development. Principles of Tissue Engineering 2000, 331-350. Academic Press, San Diego. Second ed. R.P. Lanza, R. Langer, J. Vacanti (Eds.).
14. Lewis A.S., Colton C.K. Tissue engineering for insulin replacement in diabetes. Scaffolding in Tissue Engineering 2005, 575-598. Taylor & Francis, Boca Raton, FL. P.X. Ma, J. Elisseff (Eds.).
15. Lewis A.S., Colton C.K. Engineering challenges in immunobarrier device development. Principles of Tissue Engineering 2007, 405-418. Academic Press, San Diego. Third ed. R.P. Lanza, R. Langer, J. Vacanti (Eds.).
16. Lanza R.P., Sullivan S.J., Chick W.L. Islet transplantation with immunoisolation. Diabetes 1992, 41(12):1503-1510.
17. Lanza R.P., Hayes J.L., Chick W.L. Encapsulated cell technology. Nat. Biotechnol. 1996, 14:1107-1111.
18. Fort A., Fort N., Ricordi C., Stabler C.L. Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas. Cell Transplant. 2008, 17(9):997-1003.
19. Kobayashi N. Bioartificial pancreas for the treatment of diabetes. Cell Transplant. 2008, 17(1-2):11-17.
20. Wilson J.T., Chaikof E.L. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv. Drug Deliv. Rev. 2008, 60(2):124-145.
21. Giraldo J.A., Weaver J.D., Stabler C.L. Enhancing clinical islet transplantation through tissue engineering strategies. J. Diabetes Soc. Tech. 2010, 4(5):1238-1247.
22. Krishnamurthy N.V., Gimi B. Encapsulated cell grafts to treat cellular deficiencies and dysfunction. Crit. Rev. Biomed. Eng. 2011, 39(6):473-491.
23. Robles L., Storrs R., Lamb M., Alexander M., Lakey J.R.T. Current status of islet encapsulation. Cell Transplant. 2013, (in press). 10.3727/096368913X670949.
24. Chick W.L., Perna J.J., Lauris V., Galletti P.M., Panol G., Whittemore A.D., Like A.A., Colton C.K., Lysaght M.J. An artificial pancreas utilizing living beta cells: effects on glucose hemostatis in diabetic rats. Science 1977, 197:780-782.
25. Sullivan S.J., Maki T., Borland K.M., Mahoney M.D., Solomon B.A., Muller T.E., Monaco A.P., Chick W.L. Science 1991, 252(5006):718-721.
26. Warnock G.L., Rajotte R.V. Critical mass of purified islets that induce normoglycemia after implantation into dogs. Diabetes 1988, 37:467-470.
27. Ikeda H., Kobayashi N., Tanaka Y., Nakaji S., Yong C., Okitsu T., Oshita M., Matsumoto S., Noguchi H., Narushima M., Tanaka K., Miki A., Rivas-Carrillo J.D., Soto-Gutierrez A., Navarro-Alvarez N., Tanaka K., Jun H.-S., Tanaka N., Yoon J.-W. A newly developed bioartificial pancreas successfully controls blood glucose in totally pancreatectomized diabetic pigs. Tissue Eng. 2006, 12(7):1799-1809.
28. Park J., Kalinin Y.V., Kadam S., Randall C.L., Gracias D.H. Design for a lithographically patterned bioartificial endocrine pancreas. Artif. Organs 2013, 37(12):1059-1067.
29. Lim F., Sun A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980, 210:908-910.
30. Trivedi N., Keegan M., Steil G.M., Hollister-Lock J., Hasenkamp W.M., Colton C.K., Bonner-Weir S., Weir G.C. Islets in alginate macrobeads reverse diabetes despite minimal acute insulin secretory responses. Transplantation 2001, 71(2):203-211.
31. Gazda L.S., Vinerean H.V., Laramore M.A., Diehl C.H., Hall R.D., Rubin A.L., Smith B.H. Encapsulation of porcine islets permits extended culture time and insulin independence in spontaneously diabetic BB rats. Cell Transplant. 2007, 16(6):609-620.
32. Holdcraft R.W., Gazda L.S., Circle L., Adkins H., Harbeck S.G., Meyer E.B., Bautista M.A., Martis P.C., Laramore M.A., Vinerean H.V., Hall R.D., Smith B.H. Enhancement of in vitro and in vivo function of agarose encapsulated porcine islets by changes in the islet microenvironment. Cell Transplant. 2013, (In Press). 10.3727/096368913X667033.
33. Lanza R.P., Ecker D.M., Kühtreiber W.M., Marsh J.P., Ringeling J., Chick W.L. Transplantation of islets using microencapsulation: studies in diabetic rodents and dogs. J. Mol. Med. 1999, 77:206-210.
34. Toso C., Mathe Z., Morel P., Oberholzer J., Bosco D., Sainz-Vidal D., Hunkeler D., Buhler L.H., Wandrey C., Berney T. Effect of microcapsule composition and short-term immunosuppression on intraportal biocompatibility. Cell Transplant. 2005, 14:159-167.
35. Schneider S., Feilen P.J., Brunnenmeier F., Minnemann T., Zimmermann H., Zimmermann U., Weber M.M. Long-term graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent diabetic mice. Diabetes 2005, 54:687-693.
36. Lanza R.P., Kühtreiber W.K., Eckler D., Staruk J.E., Chick W.L. Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres. Transplantation 1995, 59(10):1377-1384.
37. de Vos P., De Haan B.J., De Haan A., van Zanten J., Faas M.M. Factors influencing functional survival of microencapsulated islet grafts. Cell Transplant. 2004, 13:515-524.
38. Papas K.K., Long R.C., Constantinides I., Smabanis A. Effects of short-term hypoxia on a transformed cell-based bioartificial construct. Cell Transplant. 2000, 9(3):415-422.
39. Calafiore R., Basta G., Luca G., Calvitti M., Calabrese G., Racanicchi L., Macchiarulo G., Mancusso F., Guido L., Brunetti P. Grafts of microencapsulated pancreatic islet cells for the therapy of diabetes melliltus in nonimmunosuppressed animals. Biotechnol. Appl. Biochem. 2004, 39:159-164.
40. Darrabie M.D., Kendall W.F., Opara E.C. Characteristics of poly-l-ornithine-coated alginate microcapsules. Biomaterials 2005, 26:6846-6852.
41. Amsden B., Turner N. Diffusion characteristics of calcium alginate gels. Biotech. Bioeng. 1999, 65(5):605-610.
42. Cellesi F., Weber W., Fussenegger M., Hubbell J.A., Tirelli N. Towards a fully synthetic substitute of alginate: optimization of a thermal gelation/chemical cross-linking scheme ("tandem" gelation) for the production of beads and liquid-core capsules. Biotechnol. Bioeng. 2004, 88(6):740-749.
43. Orive G., Hernandez R.M., Gascon A.R., Calafiore R., Chang T.M.S., de Vos P., Hortelano G., Hunkeler D., Lacik I., Pedraz J.L. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol. 2004, 22(2):87-92.
44. Vijayaganapathy V., Tuch B.E. Islet transplantation and encapsulation: an update on recent developments. Rev. Diabet. Stud. 2011, 8(1):51-67.
45. O'Sullivan E.S., Vegas A., Anderson D.G., Weir G.C. Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocr. Rev. 2011, 32(6):827-844.
46. de Vos P., Lazarjani H.A., Poncelet D., Faas M.M. Polymers in cell encapsulation from an enveloped cell perspective. Adv. Drug Deliv. Rev. 2014, 67-68:15-34.
47. Sun Y., Ma X., Zhou D., Vacek I., Sun A.M. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J. Clin. Invest. 1996, 98(6):1417-1422.
48. Calafiore R., Basta G., Luca G., Lemmi A., Montanucci M.P., Calabrese G., Racanicchi L., Mancuso F., Brunetti P. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 2006, 29:137-138.
49. Hering B.J., Wijkstrom M., Graham M.L., Hardstedt M., Aasheim T.C., Jie T., Ansite J.D., Nakana M., Cheng J., Li W., Moran K., Christians U., Finnegan C., Mills C.D., Sutherland D.E., Bansal-Pakala P., Murtaugh M.P., Kirchof N., Schuurman H.J. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat. Med. 2006, 12:301-303.
50. Foster J.L., Williams G., Williams L.J., Tuch B.E. Differentiation of transplanted microencapsulated fetal pancreatic cells. Transplantation 2007, 83:1440-1448.
51. Elliott R.B., Escobar L., Tan P.L., Muzina M., Zwain S., Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5yr after xenotransplantation. Xenotransplantation 2007, 14:157-161.
52. Tuch B.E., Keogh G.W., Williams L.J., Wu W., Foster J.L., Vaithilingam V., Philips R. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 2009, 32:1887-1889.
53. Desai T.A., West T., Cohen M., Boiarski T., Rampersaud A. Nanoporous microsystems for islet cell replacement. Adv. Drug Deliv. Rev. 2004, 56:1661-1673.
54. Hauser O., Prieschl-Grassauer E., Salmonss B. Encapsulated, genetically modified cell producing in vivo therapeutics. Curr. Opin. Mol. Ther. 2004, 6(4):412-420.
55. Lanza R.P., Butler D.H., Borland K.M., Staruk J.E., Faustman D.L., Solomon B.A., Muller T.E., Rupp R.G., Maki T., Monaco A.P., et al. Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(24):11100-11104.
56. Lacy P.E., Hegre O.D., Gerasimidi-Vazeou A., Gentile F.T., Dionne K.E. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 1991, 254:1782-1784.
57. Lanza R.P., Beyer A.M., Staruk J.E., Chick W.L. Biohybrid artificial pancreas. Transplantation 1993, 56(5):1067-1072.
58. Scharp D.W., Swanson C.J., Olack B.J., Latta P.P., Hegre O.D., Doherty E.J., Gentile F.T., Flavin K.S., Ansara M.F., Lacy P.E. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 1994, 43:1167-1170.
59. Lanza R.P., Beyer A.M., Chick W.L. Xenogeneic humoral responses to islets transplanted in biohybrid diffusion chambers. Transplantation 1994, 57(9):1371-1375.
60. Aebischer P., Schluep M., Déglon N., Joseph J.-M., Hirt L., Heyd B., Goddard M., Hammang J.P., Zurn A.D., Kato A.C., Regli F., Baetge E.E. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 1996, 2(6):696-699.
61. Scharp D.W., Marchetti P. Encapsulated islets for diabetes therapy: history, current progress, and critical issues requiring solution. Adv. Drug Deliv. Rev. 2014, 67-68:35-73.
62. Dulong J.-L., Legallais C. A theoretical study of oxygen transfer including cell necrosis for the design of a bioartificial pancreas. Biotech. Bioeng. 2007, 96:990-998.
63. Erdodi G., Kang J., Yalcin B., Cakmak M., Rosenthal K.S., Grundfest-Broniatowski S., Kennedy J.P. A novel macroencapsulating immunoisolatory device: the preparation and properties of nanomat-reinforced amphiphilic co-networks deposited on perforated metal scaffold. Biomed. Microdevices 2009, 11:297-312.
64. Storrs R., Dorian R., King S.R., Lakey J., Rilo H. Preclinical development of the islet sheet. Ann. N. Y. Acad. Sci. 2001, 944:252-266.
65. King S.R., Dorian R., Storrs R.W. Requirements for encapsulation technology and the challenges for transplantation of islets of Langerhans. Graft 2001, 4:491-499.
66. Gianello P., Dufrane D. Correction of a diabetes mellitus type 1 on primate with encapsulated islet of pig pancreatic transplant. Bull. Mem. Acad. R. Med. Belg. 2007, 162:439-449.
67. Dufrane D., Goebbels R.-M., Gianello P. Alginate macroencapsulation of pig islets allows correction of Streptozotocin-induced diabetes in primates up to 6months without immunosuppression. Transplantation 2010, 90(10):1054-1062.
68. D. Dufrane, P.R.R. Gianello, J.E. Melvik, Alginate coated, collagen matrix, cellular device, preparative methods and uses thereof (2008), US Patent 8168215 B2.
69. Vériter S., Aouassar N., Adnet P.Y., Paridaens M.S., Stuckman C., Jordan B., Karroum O., Gallez B., Gianello P., Dufrane D. The impact of hyperglycemia and the presence of encapsulated islets on oxygenation within a bioartificial pancreas in the presence of mesenchymal stem cells in a diabetic Wistar rat model. Biomaterials 2011, 32(26):5945-5956.
70. Vériter S., Gianello P., Igarashi Y., Beaurin G., Ghyselinck A., Aouassar N., Jordan B., Gallez B., Dufrane D. Improvement of subcutaneous bioartificial pancreas vascularization and function by co-encapsulation of pig islets and mesenchymal stem cells in primates. Cell Transplant. 2013, (In Press). 10.3727/096368913X663550.
71. Lee J.I., Nishimura R., Saka H., Sasaki N., Kenmochi T. A newly developed immunoisolated bioartificial pancreas with cell sheet engineering. Cell Transplant. 2008, 17:51-59.
72. Brauker J., Carr-Brendel V., Martinson L., Crudele J., Johnston W., Johnson R.C. Neovascularization of synthetic membranes directed by membrane microarchitecture. J. Biomed. Mater. Res. 1995, 29(12):1517-1524.
73. Josephs S.F., Loudovaris T., Dixit A., Young S.K., Johnson R.C. In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted with Baxter immunoisolation devices. J. Mol. Med. 1999, 77:211-214.
74. Loudovaris T., Jacobs S., Young S., Maryanov D., Brauker J., Johnson R.C. Correction of diabetic nod mice with insulinomas implanted within Baxter immunoisolation devices. J. Mol. Med. 1999, 77:219-222.
75. Tibell A., Rafael E., Wennberg L., Nordenstrom J., Bergstrom M., Geller R.L., Loudovaris T., Johnson R.C., Brauker J.H., Neuenfeldt S., Wernerson A. Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans. Cell Transplant. 2001, 10:591-599.
76. Chen S.-H., Huang S.-C., Lui C.-C., Lin T.-P., Chou F.-F., Ko J.-Y. Effect of theracyte-encapsulated parathyroid cells on lumbar fusion in a rat model. Eur. Spine J. 2012, 21:1734-1739.
77. Jia X., Sharma A., Kumagai-Braesch M., Wernerson A.M., Sörenby A.K., Yamamoto S., Wang F., Tibell A.B. Extendin-4 increases the expression of hypoxia-inducible factor 1α in rat islets and preserves the endocrine cell volume of both free and macroencapsulated islet grafts. Cell Transplant. 2012, 21:1269-1283.
78. Kumagai-Braesch M., Jacobson S., Mori H., Jia X., Takahashi T., Wernerson A., Flodström-Tullberg M., Tibell A. The TheraCyte™ device protects against islet allograft rejection in immunized hosts. Cell Transplant. 2013, 22(7):1137-1146.
79. Rafael E., Wu G.S., Hultenby K., Tibell A., Wernerson A. Improved survival of macroencapsulated islets of Langerhans by pre-implantation of the immunoisolating device: a morphometric study. Cell Transplant. 2003, 12:407-412.
80. Sorenby A.K., Kumagai-Braesch M., Sharma A., Hultenby K.R., Wernerson A.M., Tibell A.B. Pre-implantation of an immunoprotective device can lower the curative dose of islets to that of free islet transplantation: studies in a rodent model. Transplantation 2008, 86:364-366.
81. La Flamme K.E., Mor G., Gong D., La Tempa T., Fusaro V.A., Grimes C.A., Desai T.A. Nanoporous alumina capsules for cellular macroencapsulation: transport and biocompatibility. Diabetes Technol. Ther. 2005, 7(5):684-694.
82. Grundfest-Broniatowski S.F., Tellioglu G., Rosenthal K.S., Kang J., Erdodi G., Yalcin B., Cakmak M., Drazba J., Bennett A., Lu L., Kennedy J.P. A new bioartificial pancreas utilizing amphiphilic membranes for the immunoisolation of porcine islets. ASAIO J. 2009, 55(4):400-405.
83. Kang J., Erdodi G., Kennedy J.P., Chou H., Lu L., Grundfest-Broniatowski S. Toward a bioartificial pancreas: diffusion of insulin and IgG across immunoprotective membranes with controlled hydrophilic channel diameters. Macromol. Biosci. 2010, 10:369-377.
84. Wu H., Avgoustiniatos E.S., Swette L., Bonner-Weir S., Weir G.C., Colton C.K. In situ electrochemical oxygen generation with an immunoisolated device. Ann. N. Y. Acad. Sci. 1999, 875:105-125.
85. Bloch K., Papismedov E., Yaviryants K., Vorobeychik M., Beer S., Vardi P. Immobilized microalgal cells as an oxygen supply system for encapsulated pancreatic islets: a feasibility study. Artif. Organs 2006, 30(9):715-718.
86. Bloch K., Papismedov E., Yavriyants K., Vorobeychik M., Beer S., Vardi P. Photosynthetic oxygen generator for bioartificial pancreas. Tissue Eng. 2006, 12(2):337-344.
87. Ludwig B., Zimerman B., Steffen A., Yavriants K., Azarov D., Reichel A., Vardi P., German T., Shabtay N., Rotem A., Evron Y., Neufeld T., Mimon S., Ludwig S., Bornstein S.R., Barkai U. A novel device for islet transplantation providing immune protection and oxygen supply. Horm. Metab. Res. 2010, 42(13):918-922.
88. Ludwig B., Rotem A., Schmid J., Weir G.C., Colton C.K., Brendel M.D., Neufeld T., Block N.L., Yavriyants K., Steffen A., Ludwig S., Chavikis T., Reichel A., Azarov D., Zimermann B., Maimon S., Balyura M., Rozenschtein T., Shabtay N., Vardi P., Bloch K., de Vos P., Schally A.V., Bornstein S.R., Barkai U. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone release hormone agonist. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(13):5022-5027.
89. Barkai U., Weir G.C., Colton C.K., Ludwig B., Bornstein S.R., Brendel M.D., Neufeld T., Bremer C., Leon A., Evron Y., Yavriyants K., Azarov D., Zimermann B., Maimon S., Shabtay N., Balyura M., Rozenschtein T., Vardi P., Bloch K., de Vos P., Rotem A. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant. 2013, 22(8):1463-1476.
90. Neufeld T., Ludwig B., Barkai U., Weir G.C., Colton C.K., Evron Y., Balyura M., Yavriyants K., Zimermann B., Azarov D., Maimon S., Shabtay N., Rozenshtein T., Lorber D., Steffen A., Willenz U., Bloch K., Vardi P., Taube R., de Vos P., Lewis E.C., Bornstein S.R., Rotem A. The efficacy of an immunoisolation membrane system for islet xenotransplantation in minipigs. PLOS One 2013, 8(8):e70150.
91. Ludwig B., Reichel A., Steffen A., Zimerman B., Schally A.V., Block N.L., Colton C.K., Ludwig S., Kersting S., Bonifacio E., Solimena M., Gendler Z., Rotem A., Barkai U., Bornstein S.R. Transplantation of human islets without immunosuppression. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(47):19054-19058.
92. Evron Y., Colton C.K., Ludwig B., Barkai U., Weir G.C., Zimermann B., Maimon S., Neufeld T., Shalev N., Goldman T., Leon A., Yavriyants K., Shabtay N., Rozenshtein T., Stefen A., Vardi P., Bloch K., de Vos P., Bornstein S.R., Rotem A. Viability and function of transplanted encapsulated islets at high density is maintained by enhanced oxygen supply 2014, (submitted for publication).
93. Emamaullee J.A., Shapiro A.M. Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant. 2007, 16:1-8.
94. Slezak L.A., Andersen D.K. Pancreatic resection: effects on glucose metabolism. World J. Surg. 2001, 25(4):452-460.
95. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl. 3):S16-S21.
96. Hellman B. The frequency distribution of the number and volume of the islets of Langerhans in man. I. Studies on non-diabetic adults. Acta Soc. Med. Ups. 1959, 64:432-460.
97. Pisania A. Development of Quantitative Methods for Quality Assessment of Islets of Langerhans May 2007, (Ph.D. Thesis), Mass. Institute of Technology, Cambridge, MA.
98. Davalli A.M., Ogawa Y., Ricordi C., Scharp D.W., Bonner-Weir S., Weir G.C. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995, 59(6):817-820.
99. Ryan E.A., Lakey J.R., Paty B.W., Imes S., Korbutt G.S., Kneteman N.M., Bigam D., Rajotte R.V., Shapiro A.M. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51(7):2148-2157.
100. Rickels M.R., Schutta M.H., Markmann J.F., Barker C.F., Naji A., Teff K.L. β-Cell function following human islet transplantation for type 1 diabetes. Diabetes 2005, 54(1):100-106.
101. Smink A.M., Faas M.M., de Vos P. Toward engineering a novel transplantation site for human pancreatic islets. Prospect. Diabetes 2013, 62(5):1357-1364.
102. Aoki T., Hui H., Umehara Y., LiCalzi S., Demetriou A.A., Rozga J., Perfetti R. Intrasplenic transplantation of encapsulated genetically engineered mouse insulinoma cells reverses streptozotocin-induced diabetes in rats. Cell Transplant. 2005, 14:411-421.
103. Simpson N.E., Khokhlova N., Oca-Cossio J.A., McMarlane S.S., Simpson C.P., Constantinidis I. Effects of growth regulation on conditionally transformed alginate-entrapped insulin-secreting cell lines in vitro. Biomaterials 2005, 26:4633-4641.
104. Kroon E., Martinson L.A., Kadoya K., Bang A.G., Kelly O.G., Eliazer S., Young H., Richardson M., Smart N.G., Cunningham J., Agulnick A.D., D'Amour K.A., Carpenter M.K., Baetge E.E. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 2008, 26:443-452.
105. L. Martinson, C. Green, E. Kroon, A. Agulnick, O. Kelly, E.E. Baetge, Encapsulation of pancreatic cells derived from human pluripotent stem cells, US Patent Publication (2013) US 8,425,928 B2.
106. Lee S.-H., Hao E., Savinov A.Y., Geron I., Strongin A.Y., Itkin-Ansari P. Human β-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation 2009, 87((7):983-991.
107. Korsgren O., Jansson J. Porcine islet-like cell clusters cure diabetic nude rats when transplanted under the kidney capsule, but not when implanted into the liver or spleen. Cell Transplant. 1994, 3:49-54.
108. Clatworthy M.R. B cell response to allograft - more common than we thought?. Am. J. Transplant. 2013, 13:1629-1630.
109. Arribas J., Borroto A. Protein ectodomain shedding. Chem. Rev. 2002, 102:4627-4638.
110. Dello S.P., Rovida E. Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol. Chem. 2002, 383:69-83.
111. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-89.
112. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 2001, 13:114-119.
113. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
114. O'Brien B.A., Harmon B.V., Cameron D.P., Allan D.J. Apoptosis is the mode of α-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes 1997, 46:750-757.
115. Trudeau J.D., Dutz J.P., Arany E., Hill D.J., Fieldus W.E., Finegood D.T. Neonatal β-cell apoptosis: a trigger for autoimmune diabetes?. Diabetes 2000, 49:1-7.
116. Turley S., Poirot L., Hattori M., Benoist C., Mathis D. Physiological β-cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J. Exp. Med. 2003, 198:1527-1537.
117. Sun E. Cell death recognition model for the immune system. Med. Hypothesis 2008, 70(3):585-596.
118. Brauker J., Martinson L.A., Young S.K., Johnson R.C. Local inflammatory response around diffusion chambers containing xenografts: nonspecific destruction of tissues and decreased local vascularization. Exp. Transplant. 1996, 61(12):1671-1677.
119. Sweet I.R., Yanay O., Waldron L., Gilbert M., Fuller J.M., Tupling T., Lernmark A., Osborne W.R. Treatment of diabetic rats with encapsulated islets. J. Cell. Mol. Med. 2008, 12:2644-2650.
120. Loudovaris T., Charlton B., Hodgson R.J., Mandel T.E. Destruction of xenografts but not allografts within cell impermeable, membranes. Transplant. Proc. 1992, 24:2291-2292.
121. + T-cells and B-cells. Transplantation 1996, 61:1678-1684.
122. McKenzie A.W., Georgiou H.M., Zhan Y., Brady J.L., Lew A.M. Protection of xenografts by a combination of immunoisolation and a single dose of anti-CD4 antibody. Cell Transplant. 2001, 10:183-193.
123. Jones K.S., Sefton M.V., Gorcynski R.M. In vivo recognition by the host adaptive immune system of microencapsulated xenogeneic cells. Transplantation 2004, 78(10):1454-1462.
124. Sharma A., Sorenby A., Wernerson A., Efendic S., Kumagai-Braesch M., Tibell A. Extendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes. Diabetologia 2006, 49:1247-1253.
125. Iwata H., Kobayashi K., Takagi T., Oka T., Yang H., Amemiya H., Tsuji T., Ito F. Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas. J. Biomed. Mater. Res. Part A 1994, 28:1003-1011.
126. Lanza R.P., Jackson R., Sullivan A., Ringeling J., McGrath C., Kühtreiber W., Chick W.L. Xenotransplantation of cells using biodegradable microcapsules. Transplantation 1999, 67(8):1105-1111.
127. Safley S.A., Kapp J.A., Weber C.J. Proliferative and cytokine responses in CTLA4-Ig-treated diabetic NOD mice transplanted with microencapsulated neonatal porcine ICCs. Cell Transplant. 2002, 11:695-705.
128. Dufrane D., Goebbels R.M., Saliez A., Guiot Y., Gianello P. Six month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation 2006, 81:1345-1353.
129. Dufrane D., Gianello P. Pig islet xenotransplantation into non-human primate model. Transplantation 2008, 86(6):753-760.
130. Dufrane D., Gianello P. Macro- or microencapsulation of pig islets to cure type 1 diabetes. World J. Gastroenterol. 2012, 18(47):6885-6893.
131. Vériter S., Gianello P., Dufrane D. Bioengineered sites for islet cell transplantation. Curr. Diab. Rep. 2013, 13:745-755.
132. Maki T., Otsu I., O'Neil J.J., Dunleavy K., Mullon C.J.P., Solomon B.A., Monaco A.P. Treatment of diabetes by xenogeneic islets without immunosuppression. Diabetes 1996, 45:342-347.
133. Tannock I.F. Oxygen diffusion and the distribution of cellular radiosensitivity in tumors. Br. J. Radiol. 1972, 45:515-524.
134. Dionne K.E., Colton C.K., Yarmush M.L. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993, 42:12-21.
135. Deters N.A., Stokes R.A., Gunton J.E. Islet transplantation: factors in short-term islet survival. Arch. Immunol. Ther. Exp. (Warsz) 2011, 59(6):421-429.
136. Carlsson P.O., Palm F., Andersson A., Liss P. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 2001, 50(3):489-495.
137. Olsson R., Olerud J., Pettersson U., Carlsson P.-O. Increased numbers of low-oxygenated pancreatic islets after intraportal islet transplantation. Diabetes 2011, 60:2350-2353.
138. Lau J., Henriksnas J., Svensson J., Carlsson P.-O. Oxygenation of islets and its role in transplantation. Curr. Opin. Organ Transplant. 2009, 14(6):688-693.
139. Davalli A.M., Ogawa Y., Ricordi C., Scharp D.W., Bonner-Weir S., Weir G.C. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995, 59(6):817-820.
140. Papas K.K., Pisania A., Wu H., Weir G.C., Colton C.K. A stirred microchamber for oxygen consumption rate measurements with pancreatic islets. Biotechnol. Bioeng. 2007, 87:1071-1082.
141. De Vos P., Van Straaten J.F.M., Nieuwenhuizen A.G., de Groot M., Ploeg R.J., De Haan B.J., Van Schilfgaarde R. Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?. Diabetes 1999, 48(7):1381-1388.
142. Schrezenmeir J., Kirchgessner J., Gero L., Kunz L.A., Beyer J., Mueller-Kliesser W. Effect of microencapsulation on oxygen distribution in islets organs. Transplantation 1994, 57:1308-1314.
143. de Groot M., Schuurs T.A., van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. J. Surg. Res. 2004, 121:141-150.
144. De Groot M., Schuurs T.A., Keizer P.P.M., Fekken S., Leuvenink H.G.D., Van Schilfgaarde R. Response of encapsulated rat pancreatic islets to hypoxia. Cell Transplant. 2003, 12:867-875.
145. Dulong J.L., Legallais C. Contributions of a finite element model for the geometric optimization of an implantable bioartificial pancreas. Artif. Organs 2002, 26(7):583-589.
146. Dulong J.L., Legallais C. A novel model of solute transport in a hollow fiber bioartificial pancreas based on a finite element method. Biotechnol. Bioeng. 2002, 78(5):576-582.
147. Dulong J.L., Legallais C. What are the relevant parameters for the geometrical optimization of an implantable bioartificial pancreas. J. Biomed. Eng. 2005, 127(7):1054-1061.
148. Lewis A.S., Fisher R.J., Weir G.C., Colton C.K. Improving oxygen supply to encapsulated cells and islets 2007, 205-241. Transworld Research Network, Kerala India. J.-P. Halle, P. De Vos, L. Rosenberg (Eds.).
149. Johnson A.S., Fisher R.J., Weir G.C., Colto C.K. Oxygen consumption and diffusion in assemblages of respiring spheres: performance enhancement of a bioartificial pancreas. Chem. Eng. Sci. 2009, 64:4470-4487.
150. Buchwald P. A local glucose-and oxygen concentration-based insulin secretion model for pancreatic islets. Theor. Biol. Med. Model. 2011, 8:20-45.
151. Avgoustiniatos E.S. Oxygen Diffusion Limitations in Pancreatic Islet Culture and Immunoisolation 2002, (Ph.D. Thesis), Mass. Institute of Technology, Cambridge, MA.
152. Pisana A., Weir G.C., O'Neil J.J., Omer A., Tchipashvili V., Lei J., Colton C.K., Bonner-Weir S. Quantitative analysis of cell composition and purity of human pancreatic islet preparations. Lab. Invest. 2010, 90:1661-1675.
153. Lazard D., Vardi P., Bloch K. Induction of beta-cell resistance to hypoxia and technologies for oxygen delivery to transplanted pancreatic islets. Diabetes Metab. Res. Rev. 2012, 28(6):475-484.
154. Klein D., Ribeiro M.M., Mendoza V., Jayaraman S., Kenyon N.S., Pileggi A., Molano R.D., Inverardi L., Ricordi C., Pastori R.L. Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets. Biochem. Biophys. Res. Commun. 2004, 323:473-478.
155. Mahato R.I. Gene expression and silencing for improved islet transplantation. J. Control. Release 2009, 140:262-267.
156. Wang X., Meloche M., Verchere C.B., Ou D., Mui A., Warnock G.L. Improving islet engraftment by gene therapy. J. Transplant. 2011, ((2011), Article ID 594851, 7 pp). 10.1155/2011/594851.
157. Hughes A., Jessup C., Drogemuller C., Mohanasundaram D., Milner C., Rojas D., Russ G.R., Coates P.T.H. Gene therapy to improve pancreatic islet transplantation for type 1 diabetes mellitus. Current. Diabetes Rev. 2010, 6(5):274-284.
158. Stokes R.A., Cheng K., Deters N., Lau S.M., Hawthorne W.J., O'Connell P.J., Stolp J., Grey S., Loudovaris T., Kay T.W., Thomas H.E., Gonzalez F.J., Gunton J.E. Hypoxia-inducible factor-1α (HIF-1α) potentiates β-cell survival after islet transplantation of human and mouse islets. Cell Transplant. 2013, 22:253-266.
159. Duncanson S., Sambanis A. Dual factor delivery of CXCL12 and exendin-4 for improved survival and function of encapsulated beta cells under hypoxic conditions. Biotech. Bioeng. 2013, 110:2292-2300.
160. Lo J.F., Wang Y., Blake A., Yu G., Harvat T.A., Jeon H., Oberholzer J., Eddington D.T. Islet preconditioning via multimodal microfluidic modulation of intermittent hypoxia. Analyt. Chem. 2012, 84:1987-1993.
161. Bloch K., Bloch O., Tarasenko I., Lazard D., Rapoport M., Vardi P. A strategy for the engineering of insulin producing cells with a broad spectrum of defense properties. Biomaterials 2011, 32(7):1816-1825.
162. Wiegand F., Kroncke K.-D., Kolb-Bachofen V. Macrophage-generated nitric oxide as cytotoxic factor in destruction of alginate-encapsulated islets. Transplantation 1993, 56:1206-1212.
163. Chae S.Y., Lee M., Kim S.W., Bae Y.H. Protection of insulin-secreting cells from nitric oxide-induced cellular damage by cross-linked hemoglobin. Biomaterials 2004, 25:843-850.
164. Chae S.Y., Kim Y.Y., Kim S.W., Bae Y.H. Prolonged glucose normalization of streptozotocin-induced diabetic mice by transplantation of rat islets coencapsulated with crosslinked hemoglobin. Transplantation 2004, 78(3):392-397.
165. Colton C.K., Stroeve P., Zahka J. Mechansim of hemogloblin facilitation of oxygen transport. J. Appl. Physiol. 1973, 35:307-309.
166. Nadithe V., Mishra D., Bae Y.H. Poly(ethylene glycol) cross-linked hemoglobin with antioxidant enzymes protects pancreatic islets from hypoxic and free radical stress and extends islet functionality. Biotech. Bioeng. 2012, 109(9):2392-2401.
167. Stagner J.I., Seelan R.S., Parthasarathy R.N., White K. Reduction of ischemic cell death in cultured islets of Langerhans by the induction of cytoglobin. Islets 2009, 1:50-54.
168. Stagner J.I., Seelan R.S., Parthasarathy R.N. Maintenance of aerobic metabolism increases immunoisolated islet survival. Islets 2011, 3:89-92.
169. Leung A., Ramaswamy Y., Munro P., Lawrie G., Nielsen L., Trau M. Emulsion strategies in the microencapsulation of cells: pathways to thin coherent membranes. Biotechnol. Bioeng. 2005, 92(1):45-53.
170. Zekorn T., Siebers U., Horcher A., Schnettler R., Zimmermann U., Bretzel R.G., Federlin K. Alginate coating of islets of Langerhans: in vitro studies on a new method for microencapsulation for immuno-isolated transplantation. Acta Diabetol. 1992, 29:41-45.
171. Kizilel S., Scavone A., Liu X., Nothias J.M., Ostaega D., Witkowski P., Millis M. Encapsulation of pancreatic islets within nano-thin functional polyethylene glycol coatings for enhanced insulin secretion. Tissue Eng. A 2010, 16(7):2217-2228.
172. Cruise G.M., Hegre O.D., Lamberti F.V., Hager S.R., Hill R., Scharp D.S., Hubbell J.A. In vitro and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes. Cell Transplant. 1999, 8(3):293-306.
173. Dong H., Fahmy T.M., Metcalfe S.M., Morton S.L., Dong X., Inverardi L., Adams D.B., Gao W., Wang H. Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice. PLOS One 2012, 7(12):e50265.
174. Teramura Y., Iwata H. Bioartificial pancreas: microencapsulation and conformal coating of islet of Langerhans. Adv. Drug Deliv. Rev. 2010, 62:827-840.
175. McMillan J.D., Wang D.I.C. Mechanisms of oxygen transfer enhancement during submerged cultivation in perfluorochemical-in-water dispersions. Ann. N. Y. Acad. Sci. 1990, 589:283-300.
176. Poncelet D., Leung R., Centomo L., Neufeld R.J. Microencapsulation of silicone oils within polyacrylamide-polyethylene membranes as oxygen carriers for bioreactor oxygenation. J. Chem. Technol. Biotechnol. 1993, 57:253-263.
177. Zekorn T., Siebers U., Bretzel R.G., Heller S., Meder U., Ruttkay H., Zimmermann U., Federlin K. Impact of the perfluorochemical FC43 on function of isolated islets. Horm. Metab. Res. 1991, 23:302-303.
178. Maillard E., Juszcak M.T., Clark A., Hughes S.J., Gray D.R.W. Perfluorodecalin-enriched fibrin matrix for human islet culture. Biomaterials 2011, 32:9282-9289.
179. Matsumoto S., Kuroda Y. Perfluorocarbon for organ preservation before transplantation. Transplantation 2002, 74(12):1804-1809.
180. Khattak S.F., Chin K.-S., Bhatia S.R., Roberts S.C. Enhancing oxygen tension and cellular function in alginate cell encapsulation devices through the use of perfluorocarbons. Biotechnol. Bioeng. 2007, 96:156.
181. Chin K., Khattak S.F., Bhatia S.R., Roberts S.C. Hydrogel-perfluorocarbon composite scaffold promotes oxygen transport to immobilized cells. Biotechnol. Prog. 2008, 24:358.
182. Gattás-Asfura K.M., Fraker C.A., Stabler C.L. Perfluorinated alginate for cellular encapsulation. J. Biomed. Mater. Res. Part A 2012, 100(8):1963-1971.
183. Goh F., Long R., Simpson N., Sambanis A. Dual perfluorocarbon method to noninvasively monitor dissolved oxygen concentration in tissue engineered constructs in vitro and in vivo. Biotechnol. Prog. 2011, 27(4):1115-1125.
184. Fraker C.A., Mendez A.J., Sabler C.L. Complementary methods for the determination of dissolved oxygen content in perfluorocarbon emulsions and other solutions. J. Phys. Chem. B 2011, 115:10547-10552.
185. Fraker C.A., Mendez A.J., Inverardi L., Ricordi C., Stabler C.L. Optimization of perfluoro nano-scale emulsions: the importance of particle size for enhanced oxygen transfer in biomedical applications. Colloids Surf. B: Biointerfaces 2012, 98:26-35.
186. Johnson A.S., O'Sullivan E., D'Aoust L.N., Omer A., Bonner-Weir S., Fisher R.J., Weir G.C., Colton C.K. Quantitative assessment of islets of Langerhans encapsulated in alginate. Tissue Eng. Part C 2011, 17(4):435-449.
187. O'Sullivan E.S., Johnson A.S., Omer A., Hollister-Lock J., Bonner-Weir S., Colton C.K., Weir G.C. Rat islet cell aggregates are superior to islets for transplantation in microcapsules. Diabetologia 2010, 53(5):937-945.
188. Trivedi N., Steil G.M., Colton C.K., Bonner-Weir S., Weir G.C. Improved vascularization of planar membrane diffusion devices following continuous infusion of vascular endothelial growth factor. Cell Transplant. 2000, 9:115-124.
189. Sigrist S., Mechine-Neuville A., Mandes K., Calenda V., Braun S., Legeay G., Bellocq J.-P., Pinget M., Kellser L. Influence of VEGF on the viability of encapsulated pancreatic rat islets after transplantation in diabetic mice. Cell Transplant. 2003, 12:627-635.
190. Sigrist S., Mechine-Neuville A., Mandes K., Calenda V., Legaey G., Bellocq J.-P., Pinget M., Kessler L. Induction of angiogenesis in omentum with vascular endothelial growth factor: influence on the viability of encapsulated rat pancreatic islets during transplantation. J. Vasc. Res. 2003, 40:359-367.
191. Hunter S.K., Kao J.M., Wang Y.E., Benda J.A., Rodgers V.G.J. Promotion of neovascularization around hollow fiber bioartificial organs using biologically active substances. ASAIO J. 1999, 45(1):37-40.
192. Tilakaratne H.K., Hunter S.K., Andracki M.E., Benda J.A., Rodgers V.G. Characterizing short-term release and neovascularization potential of multi-protein growth supplement delivered via alginate hollow fiber devices. Biomaterials 2007, 28(1):89-98.
193. Khanna O., Moya M.L., Opara E.C., Brey E.M. Synthesis of multilayered alginate microcapsules for the sustained release of fibroblast growth factor-1. J. Biomed. Mater. Res. Part A 2010, 95A:632-640.
194. Khanna O., Huang J.-J., Moya M.L., Wu C.-W., Cheng M.-H., Opara E.C., Brey E.M. FGF-1 delivery from multilayer alginate microbeads stimulates a rapid and persistent increase in vascular density. Microvasc. Res. 2013, 90:23-29.
195. McQuilling J.P., Arenas-Herrera J., Childers C., Pareta R.A., Khanna O., Jiang B., Brey E.M., Farney A.C., Opara E.C. New alginate microcapsule system for angiogenic protein delivery and immunoisolation of islets for transplantation in the rat omentum pouch. Transplant. Proc. 2011, 43:3262-3264.
196. Sakurai T., Satake A., Nagata N., Gu Y., Hiura A., Doo-Hoon K., Hori H., Tabata Y., Sumi S., Inoue K. The development of new immunoisolatory devices possessing the ability to induce neovascularization. Cell Transplant. 2003, 12:527-535.
197. Sakurai T., Satake A., Sumi S., Inoue K., Nagata N., Tabata Y., Junji M. The efficient prevascularization induced by fibroblast growth factor 2 with a collagen-coated device improves the cell survival of a bioartificial pancreas. Pancreas 2004, 28(3):e70-e79.
198. Yuasa T., Rivas-Carrillo J.D., Navarro-Alvarez N., Soto-Gutierrez A., Kubota Y., Tabata Y., Okitsu T., Noguchi H., Matsumoto S., Nakaji S., Tanaka N., Kobayashi N. Neovascularization induced around an artificial device implanted in the abdomen by the use of a gelatinized fibroblast growth factor 2. Cell Transplant. 2009, 18:683-688.
199. Miki A., Rivas-Carrillo J.D., Navarro-Alvarez N., Soto-Gutierrez A., Chen Y., Tanaka K., Narushima M., Tabata Y., Okitsu T., Noguchi H., Matsumoto S., Tanaka N., Kobayashi N. Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant. Cell Transplant. 2006, 15:893-901.
200. Marti H.J.H., Bernaudin M., Bellail A., Schoch H., Euler M., Petit E., Risau W. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 2000, 156(3):965-976.
201. Krock B.L., Skuli N., Simon M.C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2011, 2(12):1117-1133.
202. Oladipupo S., Hu S., Kovalski J., Yao J., Santeford A., Sohn R.E., Shohet R., Maslov K., Wang L.V., Arbeit J.M. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. PNAS 2011, 108(32):13264-13269.
203. 2 consumption activates hypoxia inducible factors 1 and 2 in rat insulin-secreting pancreatic beta-cells. PLOS One 2012, 7:e29807.
204. Cantley J., Grey S.T., Maxwell P.H., Withers D.J. The hypoxia response pathway and β-cell function. Diabetes Obes. Metab. 2010, 12(2):159-167.
205. Vériter S., Aouassar N., Adnet P.-Y., Paridaens M.-S., Stuckman C., Jordan B., Karroum O., Gallez B., Gianello P., Dufrane D. The impact of hyperglycemia and the presence of encapsulated islets on oxygenation within a bioartificial pancreas in the presence of mesenchymal stem cells in a diabetic Wistar rat model. Biomaterials 2011, 32:5945-5956.
206. Hunt N.C., Shelton R.M., Henderson D.J., Grover L.M. Calcium-alginate hydrogel-encapsulated fibroblasts provide sustained release of vascular endothelial growth factor. Tissue Eng. Part A 2013, 19:905-914.
207. Vallbacka J.J., Sefton M.V. Vascularization and improved in vivo survival of VEGF-secreting cells microencapsulated in HEMA-MMA. Tissue Eng. 2007, 13:2259-2269.
208. Lee J., Lee K.Y. Local and sustained vascular endothelial growth factor delivery for angiogenesis using an injectable system. Pharm. Res. 2009, 26(7):1739-1744.
209. Chan J.M., Zervantonakis I.K., Rimchala T., Polacheck W.J., Whisler J., Kamm R.D. Engineering of in vitro 3D capillary beds by self-directed angiogenic sprouting. PLOS One 2012, 7(12):e50582.
210. Sukmana I. Bioactive polymer scaffold for fabrication of vascularized engineering tissue. J. Artif. Organs 2012, 15:215-224.
211. Brady A.-C., Martino M.M., Pedraza E., Sukert S., Pileggi A., Ricordi C., Hubbell J.A., Stabler C.L. Proangiogenic hydrogels within macroporous scaffolds enhance islet engraftment in an extrahepatic site. Tissue Eng. A 2013, 19(23-24):2544-2552.
212. Phelps E.A., Headen D.M., Taylor W.R., Thulé P.M., García A.J. Vasculogenic bio-synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes. Biomaterials 2013, 34:4602-4611.
213. Cao Y., Hong A., Schulten H., Post M.J. Update on therapeutic neovascularization. Cardiovasc. Res. 2005, 65:639-648.
214. Lovett M., Lee K., Edwards A., Kaplan D.L. Vascularization strategies for tissue engineering. Tissue Eng. Part B 2009, 15(3):353-370.
215. Phelps E.A., Garcia A.J. Engineering more than a cell: vascularization strategies in tissue engineering. Curr. Opin. Biotechnol. 2010, 21(5):704-709.
216. Chung J.C.-Y., Shum-Tim D. Neovascularization in tissue engineering. Cells 2012, 1:1246-1260.
217. Nemeno-Guanzon J.G., Lee S., Berg J.R., Jo J.H., Yeo J.E., Nam B.M., Koh Y.-G., Lee J.I. Trends in tissue engineering for blood vessels. J. Biomed. Biotechnol. 2012, 2012:1-14.
218. Sukmana I. Microvascular guidance: a challenge to support the development of vascularized tissue engineering construct. Sci. World J. 2012, 2012:1-10.
219. Auger F.A., Gibot L., Lacroix D. The pivotal role of vascularization in tissue engineering. Annu. Rev. Biomed. Eng. 2013, 15:177-200.
220. Yakhneco I., Wong W.K., Katkov I.I., Itkin-Ansari P. Cryopreservation of human insulin expressing cells macro-encapsulated in a durable therapeutic immunoisolating device Theracyte. Cryo Letters 2012, 33(6):518-531.
221. M. Kumagai-Braesch, S. Jacobson, H. Mori, X. Jai, T. Takahashi, A. Wernerson, M. Flodstr[U+04E7]m-Tullberg, A. Tibel, The TheraCyte™ device protects against islet allograft rejection in immunized hosts, Cell Transplant. 22(7) 1137-1146.
222. Krishnan L., Clayton L.R., Boland E.D., Reed R.M., Hoying J.B., Williams S.K. Cellular immunoisolation for islet transplantation by a novel dual porosity electrospun membrane. Transplant. Proc. 2001, 43(9):3256-3261.
223. Pileggi A., Molano R.D., Ricordi C., Zahr E., Collins J., Valdes R., Inverardi L. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized devise. Transplantation 2006, 15;81(9):1318-1324.
224. Padera R.F., Colton C.K. Time course of membrane microarchitecture-driven neovascularization. Biomaterials 1996, 17(3):277-284.
225. Rafael E., Gazelius B., Wu G.S., Tibell A. Longitudinal studies on the microcirculation around the TheraCyte immunoisolation device, using the laser Doppler technique. Cell Transplant. 2000, 9(1):107-113.
226. Anderson J.M. Inflammatory response to implants. Trans. Am. Soc. Artif. Inter. Organs 1988, 34:101-107.
227. Zekorn T.D., Horcher A., Mellert J., Siebers U., Altug T., Emre A., Hahn H.J., Federlin K. Biocompatibility and immunology in the encapsulation of islets of Langerhans (bioartificial pancreas). Int. J. Artif. Organs 1996, 19(4):251-257.
228. Siebers U., Horcher A., Bretzel R.G., Federlin K., Zekorn T. Alginate-based microcapsules for immunoprotected islet transplantation. Ann. N. Y. Acad. Sci. 1997, 831:304-312.
229. Bridges A.W., García A.J. Anti-inflammatory polymeric coatings for implantable biomaterials and devices. J. Diabetes Sci. Technol. 2008, 2(6):984-994.
230. Intaglietta M., Johnson P.C., Winslow R.W. Microvascular and tissue oxygen distribution. Cardiovasc. Res. 1996, 32:632-643.
231. 2 microsensors for minimally invasive tissue monitoring. J. R. Soc. Interface 2004, 1:109-117.
232. Huber F.L., Latshang T.D., Goede J.S., Bloch K.E. Does venous blood gas analysis provide accurate estimates of hemoglobin oxygen affinity?. Ann. Hematol. 2013, 92(4):517-521.
233. Hughes S.J., Davies S.E., Powis S.H., Press M. Hyperoxia improves the survival of intraportally transplanted syngeneic pancreatic islets. Transplantation 2003, 75(12):1954-1959.
234. Ma Z., Moruzzi N., Catrina S.-B., Grill V., Björklund A. Hyperoxia inhibits glucose-induced insulin secretion and mitochondrial metabolism in rat pancreatic islets. Biochem. Biophys. Res. Commun. 2014, 443(1):223-228.
235. Pedraza E., Coronel M.M., Fraker C.A., Ricordi C., Stabler C.L. Preventing hypoxia-induced cell death in beta cells and islets via hydrolytically activated, oxygen-generating biomaterials. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(11):4245-4250.
236. Pedraza E., Brady A.C., Fraker C.A., Stabler C.L. Synthesis of macroporous poly(dimethylsiloxane) scaffolds for tissue engineering applications. J. Biomater. Sci. Polym. Ed. 2013, 24(9):1041-1056.
237. Ward C.L., Corona B.T., Yoo J.J., Harrison B.S., Christ G.J. Oxygen generating biomaterials preserve skeletal muscle homeostasis under hypoxic and ischemic conditions. PLOS One 2013, 8(8):e72485.
238. Coronel M.M., Stabler C.L. Engineering a local microenvironment for pancreatic islet replacement. Curr. Opinion Biotechnol. 2013, 24(50):900-908.
239. Colton C.K., Papas K.K., Pisania A., Rappel M.J., Powers D.E., Omer A., Weir G., Bonner-Weir S. Characterization of islet preparation. Cellular Transplantation from Laboratory to Clinic 2007, 85-134. Elsevier, Inc., New York. C. Halberstadt, D.F. Emerich (Eds.).